ReviewLancet regional health. Americas2025
The time has come for a vaccine against Chagas disease.
Review in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Vaccines against chronicExpert review of vaccines · 2026Review
- Glycocalyx-Driven Immunomodulation in Trypanosoma cruzi: Structures, Host Responses, Diagnostic and Therapeutic Targeting.Parasite immunology · 2026Review
- Cyclic AMP compartmentalization drives signal specificity to control vector colonization and mammalian host infection by American trypanosomes.PLoS pathogens · 2026Article
- Next-Generation Vaccines Against Neglected Diseases: New Promises from Genetically Modified Live-Attenuated Parasites and RNA Vaccines.Microorganisms · 2026Review
- Can Vaccination Prevent the Development of Chagas Disease Cardiomyopathy?JACC. Basic to translational science · 2026Article
- Cyclic AMP compartmentalization drives signal specificity to control vector colonization and mammalian host infection by American trypanosomes.bioRxiv : the preprint server for biology · 2025Article
- Integrating Cellular Immune Biomarkers with Machine Learning to Identify Potential Correlates of Protection for aVaccines · 2025Article
- The patent landscape of Chagas disease vaccines indicates major underinvestment in an emerging global health threat.Nature biotechnology · 2025Article
- RNA and protein immunization withFrontiers in cellular and infection microbiology · 2025Article
- Trypanocidal Treatment for Chronic Chagas Disease: Past, Present, and Future.Revista da Sociedade Brasileira de Medicina Tropical · 2025Review
- Editorial: Immunoregulatory cells: balancing immune responses during pathogen infections.Frontiers in immunology · 2025Article
- Towards a map of the immune system manipulation network byFrontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite many studies, there is still no vaccines for Chagas Disease (CD), which affects approximately 7 million people mainly in Latin America. To make matters worse, the only two drugs available have proved efficacy only when administered during the acute phase of the disease. Here, we discuss recent advances towards the development of a CD vaccine including (i) better understanding of the role of elements involved in immune responses and host defense against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.